Co-Diagnostics Inc (NAS:CODX)

Q1 2026 Co-Diagnostics Inc Earnings Call Transcript

May 14, 2026 / 08:30 PM GMT

Release Date Price: $1.63 (+1.87%)

Transcript 10-Q8-K

Key Points

Positve

Co-Diagnostics Inc (CODX) has completed enrollment in a clinical study for their upper respiratory multiplex test, with over 1,400 patients enrolled.
The company is advancing its strategy in India through its Coursera joint venture, which has a nationwide commercial presence and 15 clinical laboratory PCR tests cleared by India's regulatory body.
Co-Diagnostics Inc (CODX) is progressing its Comira joint venture in Saudi Arabia, securing industrial land allocation and moving forward with facility development.
The company is leveraging machine learning and algorithmic analysis within its platform, enhancing operational efficiency and real-time monitoring capabilities.
Co-Diagnostics Inc (CODX) is preparing to manufacture the PCRPro instrument and consumables locally in India, representing a significant step toward commercialization.

Negative

Total revenue for the first quarter of 2026 was only $146,000, compared to $50,000 in the same period last year, indicating limited revenue growth.
The company reported a net loss of $9.1 million for the quarter, an increase from a net loss of $7.5 million in the same period last year.
Operating expenses increased to $9.2 million, driven by higher research and development spending, impacting profitability.
Co-Diagnostics Inc (CODX) expects to continue generating operating losses in the near term, indicating ongoing financial challenges.
The company anticipates that additional capital will be required to fully execute its commercialization and development plans, highlighting potential funding needs.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CODX.OQ - Co-Diagnostics Inc
Q1 2026 Co-Diagnostics Inc Earnings Call
May 14, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you for standing by. At this time, I would like to welcome everyone to the CoDiagnostics, Inc. First Quarter 2026 Earnings Webcast.

All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. I would now like to turn the conference over to Andrew Benson, Head of Investor Relations. The floor is yours.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good afternoon,

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.